Yazar "Ersatir, Mehmet" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Cytotoxic and apoptotic potential of some coumarin and 2-amino-3-carbonitrile selenophene derivatives in prostate cancer
    (Tubitak Scientific & Technological Research Council Turkey, 2021) Yildirim, Metin; Ersatir, Mehmet; Arslan, Badel; Giray, Elife Sultan
    3-acetyl coumarin derivatives (1a-d) are formed as a result of condensation of salicylaldehyde derivatives and ethyl acetoacetate and were converted into coumarin-selenophene hybrid compounds (2a-d) in the basic medium by modified Gewald reaction in the presence of malononitrile and selenium. Products are characterized by nuclear magnetic resonance (NMR). The prepared compounds are screened for their anticancer activity against DU-145 cell line. In addition, selected target compounds are evaluated for apoptosis and oxidative stress on DU-145 (prostate carcinoma) cell lines.
  • [ X ]
    Öğe
    Green synthesis of 2-amino-3-cyanopyridines via a cooperative vinylogous anomeric-based oxidation and their antiproliferative effects on liver, breast, and prostate cancer studies
    (Taylor & Francis Inc, 2021) Ersatir, Mehmet; Yildirim, Metin
    2-Amino-3-cyanopyridine derivatives were synthesized in an ultrasonic bath and one pot four-component reactions with high yields, in a short time, without solvent and catalyst, and anticancer activity studies on MCF7, DU145, and HepG2 cell lines were investigated. 18 compounds were synthesized in 4-25 min time interval and 85-99% yield. Among these compounds, the IC50 values in 7a, 6a, and 3a on MCF7 breast cancer cell line was found to be 1.80, 1.95, and 2.50 mu M, respectively, while the values in the HepG2 liver cancer cell line were 7.71, 7.90, and 8.05 mu M, respectively. In studies conducted in the DU145 prostate cancer cell line, IC50 values of compounds 1b, 2b, and 8b were found to be 9.90, 10.10, and 15.30 mu M, respectively.
  • [ X ]
    Öğe
    Potential Protective Effects of Ruta Chalepensis L. Extracts Against Gentamicin-Induced Nephrotoxicity via Reduction on Apoptotic, DNA Damage and Oxidative Stress Markers in Mice
    (Taylor & Francis Ltd, 2023) Yildirim, Metin; Ersatir, Mehmet; Degirmenci, Ulas; Yigin, Akin; Unal, Mustafa Boyraz; Guldur, Muhammet Emin; Demirkol, Onur
    In this study, the protective effects of Ruta chalepensis L. extracts on the extent of tissue damage in gentamicin-induced nephrotoxicity have been investigated. Ruta chalepensis L. extracts were prepared by subcritical water and ultrasound-assisted organic solvent extraction methods. Protective activity of Ruta chalepensis L. extracts on Gentamicin-induced nephrotoxicity is investigated by apoptotic, DNA damage, oxidative stress markers and evaluating histopathological in kidney tissue of mice. Gentamicin significantly increased Caspase-3 and -8 activities, NO levels, serum creatinine and BUN, while 8-OHdG and MDA levels were significantly decreased with Ruta chalepensis L. extract treatment. In addition, Ruta chalepensis L. extracts treatment significantly increased CAT and SOD activities. Histopathological alterations in Gentamicin group were significantly diminished by application of Ruta chalepensis L. extracts. These results suggest that treatment with Ruta chalepensis L. extracts may ameliorate renal dysfunction and structural damage through the reduction of oxidative stress and apoptosis in the kidney.
  • [ X ]
    Öğe
    Recent advances on biologically active coumarin-based hybrid compounds
    (Springer Birkhauser, 2023) Yildirim, Metin; Poyraz, Samet; Ersatir, Mehmet
    Coumarin hybrids have been designed and synthesized as an important new strategy in the field of medicinal chemistry. Coumarin core has been shown to form various compounds to combat several diseases including microbial, cancer, inflammatory, and neurodegenerative disorders. Recently, a number of coumarin-based drugs (e.g., coumadin, acenocoumarol, dicoumarol, phenprocoumon, and novobiocin) have been FDA-approved and are in the clinic, and several coumarin-containing compounds are in clinical trials. Our group classified coumarin-based hybrid compounds into groups showing shared biological activities and discussed their potential therapeutic targets.